

# Histone Deacetylase Inhibitor Panobinostat Induces Clinical Alterations in Gene Expression Profiles in Cutaneous T-

Clinical Cancer Research

14, 4500-4510

DOI: [10.1158/1078-0432.ccr-07-4262](https://doi.org/10.1158/1078-0432.ccr-07-4262)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epigenetics and dermatological disease. <i>Pharmacogenomics</i> , 2008, 9, 1835-1850.	0.6	52
2	Cutaneous T-cell lymphoma and emerging therapies. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e69-e79.	0.8	0
3	Histone Deacetylation. <i>Drugs in R and D</i> , 2008, 9, 369-383.	1.1	36
4	Clinical Studies of Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 3958-3969.	3.2	334
5	Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2009, 20, 413-424.	0.6	86
6	Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. <i>Future Oncology</i> , 2009, 5, 601-612.	1.1	119
7	Epigenetics of neurological cancers. <i>Future Oncology</i> , 2009, 5, 1615-1629.	1.1	20
8	IgA nephropathy associated with cutaneous T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 2083-2085.	0.6	9
9	The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells <i>in vitro</i> and <i>in vivo</i> with particular efficacy for small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2221-2231.	1.9	106
10	LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. <i>Human Molecular Genetics</i> , 2009, 18, 3645-3658.	1.4	100
11	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5410-5417.	0.8	687
12	Epigenetic mechanisms in glioblastoma multiforme. <i>Seminars in Cancer Biology</i> , 2009, 19, 188-197.	4.3	154
13	Targeting histone deacetylases for the treatment of disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 826-852.	1.6	41
14	Molecular Epigenetics and Genetics in Neuro-Oncology. <i>Neurotherapeutics</i> , 2009, 6, 436-446.	2.1	52
15	Natural killer-cell neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 245-252.	1.2	27
16	The future of small molecule inhibitors in lymphoma. <i>Current Oncology Reports</i> , 2009, 11, 378-385.	1.8	2
17	The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. <i>Journal of Pathology</i> , 2009, 218, 467-477.	2.1	46
18	Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 97-101.	1.2	89

#	ARTICLE	IF	CITATIONS
19	Targeting tumor angiogenesis with histone deacetylase inhibitors. <i>Cancer Letters</i> , 2009, 280, 145-153.	3.2	218
20	Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. <i>Cancer Letters</i> , 2009, 280, 233-241.	3.2	358
21	Histone deacetylase inhibitors as anti-neoplastic agents. <i>Cancer Letters</i> , 2009, 280, 192-200.	3.2	146
22	Biomarkers for predicting clinical responses to HDAC inhibitors. <i>Cancer Letters</i> , 2009, 280, 177-183.	3.2	89
23	Histone Deacetylase Inhibitors in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 5459-5468.	0.8	793
24	Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. <i>Current Opinion in Hematology</i> , 2009, 16, 299-305.	1.2	20
25	Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. <i>Blood</i> , 2009, 113, 4038-4048.	0.6	50
26	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. <i>Blood</i> , 2009, 114, 380-393.	0.6	108
27	How I treat mycosis fungoides and S�azary syndrome. <i>Blood</i> , 2009, 114, 4337-4353.	0.6	144
28	Epigenetic Modulation in Hematologic Malignancies: Challenges and Progress. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-12.	2.3	8
29	Mantle cell lymphoma in relapse: the role of emerging new drugs. <i>Current Opinion in Oncology</i> , 2010, 22, 419-423.	1.1	15
30	Role of Histone Deacetylases and Their Inhibitors in Cancer Biology and Treatment. <i>Current Clinical Pharmacology</i> , 2010, 5, 196-208.	0.2	62
31	Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development. <i>Current Molecular Medicine</i> , 2010, 10, 596-607.	0.6	0
32	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	1.7	144
33	Recent advances in histone deacetylase targeted cancer therapy. <i>Surgery Today</i> , 2010, 40, 809-815.	0.7	43
34	Targeted treatment and new agents in peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 33-44.	0.7	26
35	Targeting histone deacetylases in the treatment of B- and T-cell malignancies. <i>Investigational New Drugs</i> , 2010, 28, 58-78.	1.2	59
36	Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. <i>Investigational New Drugs</i> , 2010, 28, 3-20.	1.2	123

#	ARTICLE	IF	CITATIONS
37	Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2010, 3, 5.	6.9	373
38	HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus- $\beta$ gal mediated suicide gene therapy in HNSCC xenograft mouse model. <i>International Journal of Cancer</i> , 2010, 126, 733-742.	2.3	16
39	Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. <i>International Journal of Cancer</i> , 2010, 127, 2199-2208.	2.3	79
40	Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise. <i>Blood Reviews</i> , 2010, 24, 69-82.	2.8	13
41	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 256-267.	1.2	74
42	Histone deacetylases and the immunological network: implications in cancer and inflammation. <i>Oncogene</i> , 2010, 29, 157-173.	2.6	177
43	Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway. <i>Pharmaceuticals</i> , 2010, 3, 1446-1455.	1.7	17
44	Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2441-2469.	1.7	55
45	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2674-2688.	1.7	7
47	Clinical Toxicities of Histone Deacetylase Inhibitors. <i>Pharmaceuticals</i> , 2010, 3, 2751-2767.	1.7	281
48	Three-Dimensional Cell Growth Confers Radioresistance by Chromatin Density Modification. <i>Cancer Research</i> , 2010, 70, 3925-3934.	0.4	165
49	New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies. <i>Clinical Cancer Research</i> , 2010, 16, 5608-5617.	3.2	21
50	Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1113-1127.	1.9	12
51	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5499-5510.	3.2	71
52	Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 554-565.	3.2	65
53	The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11032-11037.	3.3	50
54	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 997-1008.	1.1	215
55	Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2010, 10, 898-913.	0.8	30

#	ARTICLE	IF	CITATIONS
56	Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. <i>Expert Review of Hematology</i> , 2010, 3, 187-203.	1.0	31
57	Histone deacetylases and epigenetic therapies of hematological malignancies. <i>Pharmacological Research</i> , 2010, 62, 18-34.	3.1	121
58	Personalized therapies in the cancer "omics" era. <i>Molecular Cancer</i> , 2010, 9, 202.	7.9	52
59	The Role of Histone Deacetylase Inhibitors in the Treatment of Patients With Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 98-109.	0.2	25
60	New Strategies to Optimize Outcomes in Patients With T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S84-S87.	0.2	1
61	Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2706.	3.8	339
62	Peripheral Tâ€cell lymphoma gene expression profiling and potential therapeutic exploitations. <i>British Journal of Haematology</i> , 2010, 150, 21-27.	1.2	17
63	Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. <i>Leukemia and Lymphoma</i> , 2011, 52, 1463-1473.	0.6	37
64	HDAC Inhibitors and Cancer Therapy. , 2011, 67, 175-195.		55
65	Promises and challenges of anticancer drugs that target the epigenome. <i>Epigenomics</i> , 2011, 3, 547-565.	1.0	21
66	Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5620-5625.	3.3	175
67	Epigenetics and Disease. , 2011, , .		5
68	Clinical development of panobinostat in classical Hodgkinâ€™s lymphoma. <i>Expert Review of Hematology</i> , 2011, 4, 245-252.	1.0	18
69	Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2011, 50, 165-171.	0.5	12
70	Mycosis fungoÃdes and SÃzary syndrome. <i>Hematologie</i> , 2011, 17, 411-421.	0.0	0
71	Romidepsin in the treatment of cutaneous T-cell lymphoma. <i>Journal of Blood Medicine</i> , 2011, 2, 37.	0.7	27
72	Accumulation of Specific Epigenetic Abnormalities During Development and Progression of T Cell Leukemia/Lymphoma. , 2011, , .		0
73	Interpreting clinical assays for histone deacetylase inhibitors. <i>Cancer Management and Research</i> , 0, , 117.	0.9	3

#	ARTICLE	IF	CITATIONS
74	HDACi - going through the mechanisms. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 340.	3.0	47
75	Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression. <i>PLoS ONE</i> , 2011, 6, e27178.	1.1	16
76	Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S3778.	0.4	2
77	Epigenetic Multiple Modulators. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2749-2787.	1.0	11
78	HIV cure and eradication: how will we get from the laboratory to effective clinical trials?. <i>Aids</i> , 2011, 25, 885-897.	1.0	113
79	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. <i>Blood</i> , 2011, 117, 3658-3668.	0.6	128
80	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 5827-5834.	0.6	428
81	Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. <i>Haematologica</i> , 2011, 96, 712-719.	1.7	91
82	Clinical Applications of Histone Deacetylase Inhibitors. , 2011, , 597-615.		2
83	Evolving Insights in the Pathogenesis and Therapy of Cutaneous T-cell lymphoma (Mycosis Fungoides) Tj ETQq1 1 0.784314 rgBT /Ove 1.2 127		
84	Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. <i>Leukemia</i> , 2011, 25, 362-365.	3.3	30
85	Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 226-235.	3.3	144
86	LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. <i>Leukemia</i> , 2011, 25, 575-587.	3.3	45
87	Romidepsin: a novel histone deacetylase inhibitor for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1151-1158.	1.9	129
88	Treatment algorithms for mature T-cell and natural killer-cell neoplasms. <i>Future Oncology</i> , 2011, 7, 1101-1112.	1.1	9
89	Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 55-63.	1.1	48
90	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 805-813.	1.1	42
91	The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy. <i>Journal of Orthopaedic Research</i> , 2011, 29, 623-632.	1.2	24

#	ARTICLE	IF	CITATIONS
92	Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 928-948.	2.0	61
93	Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. <i>Cancer</i> , 2011, 117, 336-342.	2.0	116
94	The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients. <i>Leukemia Research</i> , 2011, 35, 295-296.	0.4	10
95	Antiangiogenic Therapies in Non-Hodgkin's Lymphoma. <i>Current Cancer Drug Targets</i> , 2011, 11, 1030-1043.	0.8	12
96	Classifying short gene expression time-courses with Bayesian estimation of piecewise constant functions. <i>Bioinformatics</i> , 2011, 27, 946-952.	1.8	14
97	Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737. <i>Cancer Research</i> , 2011, 71, 3603-3615.	0.4	51
98	Belinostat: clinical applications in solid tumors and lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1723-1732.	1.9	34
99	New drug therapies in peripheral T-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 457-472.	1.1	28
100	Manipulating Protein Acetylation in Breast Cancer: A Promising Approach in Combination with Hormonal Therapies?. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-15.	3.0	28
101	Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: "To Be or Not to Be Acetylated?". <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-15.	3.0	18
102	Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. <i>Journal of Investigative Dermatology</i> , 2012, 132, 517-525.	0.3	11
103	Romidepsin for Cutaneous T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 3509-3515.	3.2	77
104	Intrinsic and Extrinsic Apoptotic Pathway Signaling as Determinants of Histone Deacetylase Inhibitor Antitumor Activity. <i>Advances in Cancer Research</i> , 2012, 116, 165-197.	1.9	101
105	Chromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5364-5369.	3.3	53
106	Development therapeutics. , 0, , 616-631.		0
107	Cutaneous T-cell lymphoma: update on treatment. <i>International Journal of Dermatology</i> , 2012, 51, 1019-1036.	0.5	27
108	Trials with "epigenetic" drugs: An update. <i>Molecular Oncology</i> , 2012, 6, 657-682.	2.1	208
109	Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. <i>Breast Cancer Research</i> , 2012, 14, R79.	2.2	213

#	ARTICLE	IF	CITATIONS
110	Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 671-704.	0.9	16
111	HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. <i>Future Medicinal Chemistry</i> , 2012, 4, 471-486.	1.1	61
112	Novel therapeutic agents for cutaneous T-Cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2012, 5, 24.	6.9	47
113	Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled <sup>14</sup> C material in advanced cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 513-522.	1.1	51
114	HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. <i>Immunology and Cell Biology</i> , 2012, 90, 85-94.	1.0	392
115	Pan-Histone Deacetylase Inhibitor Panobinostat Sensitizes Gastric Cancer Cells to Anthracyclines via Induction of CITED2. <i>Gastroenterology</i> , 2012, 143, 99-109.e10.	0.6	36
116	Tumor-specific MAGE proteins as regulators of p53 function. <i>Cancer Letters</i> , 2012, 325, 11-17.	3.2	34
117	Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. <i>British Journal of Cancer</i> , 2012, 106, 77-84.	2.9	136
118	Mechanisms of Resistance to Histone Deacetylase Inhibitors. <i>Advances in Cancer Research</i> , 2012, 116, 39-86.	1.9	91
119	Panobinostat for the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 733-747.	1.9	34
120	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1820-1823.	0.6	109
121	Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. <i>OncoTargets and Therapy</i> , 2012, 5, 67.	1.0	17
122	Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. <i>Cancer Management and Research</i> , 2012, 4, 75.	0.9	35
123	Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1245-1251.	0.8	21
124	HDAC inhibitors in HIV. <i>Immunology and Cell Biology</i> , 2012, 90, 47-54.	1.0	113
125	A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 1096-1106.	1.2	45
126	Recent Advances in the Management of Cutaneous Lymphomas. <i>Seminars in Oncology</i> , 2012, 39, 150-162.	0.8	6
127	Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2012, 130, 694-704.	2.3	47



#	ARTICLE	IF	CITATIONS
129	T-Cell Lymphomas. , 2013, , .		1
130	Deregulated Chromatin Remodeling in the Pathobiology of Brain Tumors. <i>NeuroMolecular Medicine</i> , 2013, 15, 1-24.	1.8	19
131	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 974-985.	1.2	28
132	The Role of Angiogenesis in Human Non-Hodgkin Lymphomas. <i>Neoplasia</i> , 2013, 15, 231-238.	2.3	70
133	Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. <i>Nature Reviews Genetics</i> , 2013, 14, 765-780.	7.7	373
134	VPA response in SMA is suppressed by the fatty acid translocase CD36. <i>Human Molecular Genetics</i> , 2013, 22, 398-407.	1.4	50
135	Toxicological and metabolic considerations for histone deacetylase inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 441-457.	1.5	46
136	Panobinostat activity in both bexarotene-exposed and -na~ve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. <i>European Journal of Cancer</i> , 2013, 49, 386-394.	1.3	124
137	Comparison of HDAC inhibitors in clinical development. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 993-1001.	1.4	173
138	Epigenetic Alterations in Pancreatic Cancer. , 2013, , 185-207.		1
139	Metalloprotein~Inhibitor Binding: Human Carbonic Anhydrase II as a Model for Probing Metal~Ligand Interactions in a Metalloprotein Active Site. <i>Inorganic Chemistry</i> , 2013, 52, 12207-12215.	1.9	30
140	The role of cytokines in the initiation and progression of myelofibrosis. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 133-145.	3.2	128
141	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-744.	0.9	38
142	A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 747-755.	1.1	14
143	Angiogenesis as a treatment target in leukemia. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 229-242.	0.7	1
144	Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives. <i>Current Pharmaceutical Design</i> , 2013, 19, 578-613.	0.9	69
145	Romidepsin for cutaneous T-cell lymphoma. <i>Future Oncology</i> , 2013, 9, 1819-1827.	1.1	19
146	The development and potential clinical utility of biomarkers for HDAC inhibitors. <i>Drug Discoveries and Therapeutics</i> , 2013, , .	0.6	8

#	ARTICLE	IF	CITATIONS
147	Histone Deacetylase Inhibitors in Cutaneous T-cell Lymphoma. <i>Journal of the Dermatology Nurses' Association</i> , 2013, 5, 305-313.	0.1	2
148	Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 4499-4507.	3.2	55
149	Panobinostat in lymphoid and myeloid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1211-1223.	1.9	39
150	Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma. <i>Journal of Biological Chemistry</i> , 2013, 288, 8332-8341.	1.6	77
151	Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. <i>Blood</i> , 2013, 122, 2104-2113.	0.6	52
152	Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches. <i>Clinical Investigation</i> , 2013, 3, 571-594.	0.0	2
153	A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. <i>British Journal of Cancer</i> , 2013, 109, 909-914.	2.9	54
155	Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G2 Delay and Mitotic Defects. <i>Scientific Reports</i> , 2013, 3, 2640.	1.6	12
156	LBH589 Promotes Osteogenic and Dentinogenic Differentiation of Stem Cells from the Apical Papilla by Inhibiting Histone Deacetylation. <i>Journal of Hard Tissue Biology</i> , 2014, 23, 335-342.	0.2	1
157	Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications. <i>International Journal of Biological Sciences</i> , 2014, 10, 757-770.	2.6	133
158	Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1971.	1.0	10
159	Isoform-Selective HDAC Inhibition in Autoimmune Disease Nicole L Regna1* and Christopher M Reilly2. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2014, 05, .	1.5	2
160	Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 457-467.	1.9	28
161	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1089-1098.	1.1	38
162	Use of panobinostat in patients with classical Hodgkin lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 203-210.	0.7	1
163	Modeling the Timing of Antiretroviral Drug Administration during HIV Treatment. <i>Journal of Virology</i> , 2014, 88, 14050-14056.	1.5	19
164	Altered Histone Modifications in Gliomas. <i>Brain Tumor Research and Treatment</i> , 2014, 2, 7.	0.4	54
165	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. <i>Blood</i> , 2014, 123, 1341-1352.	0.6	107

#	ARTICLE	IF	CITATIONS
166	Tentative first steps to eradicate latent HIV. <i>Lancet HIV</i> , 2014, 1, e2-e3.	2.1	1
167	Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 837-851.	2.0	58
168	Epigenetic drugs against cancer: an evolving landscape. <i>Archives of Toxicology</i> , 2014, 88, 1651-1668.	1.9	50
169	A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 89-98.	0.8	35
171	From empiric to mechanism-based therapy for peripheral T cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 249-262.	0.7	16
172	Predicting response to epigenetic therapy. <i>Journal of Clinical Investigation</i> , 2014, 124, 47-55.	3.9	78
173	Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. <i>British Journal of Haematology</i> , 2015, 170, 96-109.	1.2	51
174	Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. <i>Genes and Cancer</i> , 2015, 6, 184-213.	0.6	78
175	Critical appraisal of belinostat in the management of T-cell lymphoma &ndash; patient considerations. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2015, , 109.	1.2	0
176	Analysis of class I and II histone deacetylase gene expression in human leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3426-3433.	0.6	20
177	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 87-95.	1.1	40
178	Follow-up of patients with mycosis fungoides after interferon $\gamma$ treatment failure. <i>Postepy Dermatologii i Alergologii</i> , 2015, 2, 67-72.	0.4	6
179	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e326-e333.	2.2	50
180	Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. <i>Survey of Ophthalmology</i> , 2015, 60, 524-535.	1.7	48
181	Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. <i>Nucleic Acids Research</i> , 2015, 43, e97-e97.	6.5	430
182	Histone Deacetylase Inhibitors in Medical Therapeutics. , 2016, , 633-655.		3
183	Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. <i>OncoTargets and Therapy</i> , 2016, 9, 2783.	1.0	11
184	DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. <i>Scientifica</i> , 2016, 2016, 1-11.	0.6	26

#	ARTICLE	IF	CITATIONS
185	Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 144, 487-537.	0.9	29
186	Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 275-288.	3.3	118
187	Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 151-165.	2.0	118
188	Albumin-Polymer-Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles. <i>ACS Macro Letters</i> , 2016, 5, 1089-1094.	2.3	34
189	Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research. <i>International Journal of Cardiology</i> , 2016, 219, 396-403.	0.8	34
190	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 228-240.	2.0	29
191	An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 687-696.	1.9	21
192	Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. <i>Xenobiotica</i> , 2017, 47, 354-368.	0.5	27
193	Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. <i>Epigenetics</i> , 2017, 12, 353-369.	1.3	36
194	Risk Factors for 30-Day Readmission in Adults with Sickle Cell Disease. <i>American Journal of Medicine</i> , 2017, 130, 601.e9-601.e15.	0.6	28
195	Cellular analysis of the action of epigenetic drugs and probes. <i>Epigenetics</i> , 2017, 12, 308-322.	1.3	5
196	Discovery of ErbB/HDAC inhibitors by combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib, BMS-690514, neratinib, and TAK-285. <i>Chinese Chemical Letters</i> , 2017, 28, 1220-1227.	4.8	22
197	Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. <i>Blood</i> , 2017, 130, 2073-2083.	0.6	42
198	Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2017, 92, 1085-1102.	2.0	104
199	A strategy for effective latent HIV reactivation using subtherapeutic drug doses. <i>Scientific Reports</i> , 2017, 7, 16644.	1.6	0
200	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 27-37.	1.4	45
201	Targeting histone deacetylases in T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1306-1319.	0.6	84
202	Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Pharmacology</i> , 2017, 8, 495.	1.6	48

#	ARTICLE	IF	CITATIONS
203	Clinical Applications of Histone Deacetylase Inhibitors. , 2017, , 605-621.		7
204	Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals, 2017, 10, 40.	1.7	33
205	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. Neurologia Medico-Chirurgica, 2017, 57, 331-342.	1.0	36
206	HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget, 2017, 8, 80109-80123.	0.8	23
207	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Leukemia and Lymphoma, 2018, 59, 2904-2910.	0.6	11
208	The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). Current Hematologic Malignancy Reports, 2018, 13, 13-24.	1.2	21
209	Blazing Signature Filter: a library for fast pairwise similarity comparisons. BMC Bioinformatics, 2018, 19, 221.	1.2	6
210	Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Frontiers in Immunology, 2018, 9, 1452.	2.2	26
211	Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies. , 2018, , 849-912.		29
212	Small molecule inhibitors for cutaneous T-cell lymphomas. Expert Opinion on Orphan Drugs, 2018, 6, 345-350.	0.5	0
213	Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunology, Immunotherapy, 2018, 67, 1481-1489.	2.0	59
214	Integrating novel systemic therapies for the treatment of mycosis fungoides and SÅ©zary syndrome. Best Practice and Research in Clinical Haematology, 2018, 31, 322-335.	0.7	8
215	Mycosis fungoides and SÅ©zary syndrome: 2019 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2019, 94, 1027-1041.	2.0	77
216	Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and SÅ©zary syndrome. Best Practice and Research in Clinical Haematology, 2019, 32, 239-252.	0.7	5
218	Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. International Journal of Medical Sciences, 2019, 16, 424-442.	1.1	51
219	Mechanism of Action for HDAC Inhibitorsâ€”Insights from Omics Approaches. International Journal of Molecular Sciences, 2019, 20, 1616.	1.8	48
220	Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. Journal of Medicinal Chemistry, 2019, 62, 2651-2665.	2.9	28
221	Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. , 2020, , 1948-1964.e5.		0

#	ARTICLE	IF	CITATIONS
222	Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 827-830.	1.1	10
223	Targeting epigenetic regulators in the treatment of T-cell lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 127-139.	1.0	8
224	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 56-64.	1.3	15
225	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. <i>Cancers</i> , 2020, 12, 3498.	1.7	11
226	Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs. <i>Journal of Receptor and Signal Transduction Research</i> , 2022, 42, 100-108.	1.3	1
227	Recent Update of HDAC Inhibitors in Lymphoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 576391.	1.8	48
228	Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 278.	3.5	27
229	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 14609-14614.	7.2	22
230	Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1476-1483.	1.3	21
231	PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112411.	2.6	27
232	Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 425.	1.8	28
233	Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF- $\kappa$ B and autophagy on panobinostat cytotoxicity. <i>European Journal of Pharmacology</i> , 2020, 875, 173050.	1.7	20
234	Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4377.	1.8	5
235	Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. <i>Clinical Cancer Research</i> , 2020, 26, 1000-1008.	3.2	26
236	Histone Mutations and Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, , .	0.8	3
237	Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. <i>Seminars in Hematology</i> , 2021, 58, 103-113.	1.8	4
238	Direct Amidation to Access 3-Amido-1,8-Naphthalimides Including Fluorescent Scriptaid Analogues as HDAC Inhibitors. <i>Cells</i> , 2021, 10, 1505.	1.8	6
239	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8486-8509.	2.9	28

#	ARTICLE	IF	CITATIONS
240	HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. <i>Cancers</i> , 2021, 13, 3575.	1.7	35
241	Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy. <i>Pharmacological Research</i> , 2021, 170, 105695.	3.1	38
242	Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2021, 96, 1313-1328.	2.0	21
243	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie</i> , 2020, 132, 14717-14722.	1.6	4
245	Current Epigenetic Therapy for T-Cell Lymphoma. , 2013, , 279-296.		2
246	Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 87-110.	0.1	1
247	Review of the Treatment of Mycosis Fungoides and S�zary Syndrome : A Stage-Based Approach. <i>International Journal of Health Sciences</i> , 2013, 7, 220-239.	0.4	22
248	Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy. <i>PLoS ONE</i> , 2014, 9, e89750.	1.1	7
249	Histone Deacetylases and Cancer-Associated Angiogenesis: Current Understanding of the Biology and Clinical Perspectives. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 119-137.	0.2	18
250	Current perspective of histone deacetylase inhibitors: A review. <i>International Journal of Pharmaceutical Chemistry and Analysis</i> , 2020, 5, 108-122.	0.1	1
251	Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. <i>Oncotarget</i> , 2013, 4, 2225-2236.	0.8	64
252	Interpreting clinical assays for histone deacetylase inhibitors. <i>Cancer Management and Research</i> , 2011, 3, 117.	0.9	33
253	The Role of Phenolic Compounds in the Fight against Cancer – A Review. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1236-1258.	0.9	211
254	A Novel Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivative, N25, Exhibiting Improved Antitumor Activity in both Human U251 and H460 Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 4331-4338.	0.5	9
255	Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of S�zary Cells. <i>Frontiers in Oncology</i> , 2021, 11, 775253.	1.3	3
256	Epigenetic Profiling of Gliomas. , 2009, , 615-650.		1
257	Molecular Genetics of Mature T/NK Neoplasms. <i>Molecular Pathology Library</i> , 2010, , 309-327.	0.1	0
259	Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma. , 2012, , 349-372.		0

#	ARTICLE	IF	CITATIONS
260	Syndromes and Clinical Management Issues Associated with T-Cell Lymphomas. , 2013, , 317-331.		0
261	Cutaneous T-Cell Lymphoma. , 2014, , 133-167.		0
262	Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. , 2014, , 2060-2075.e5.		0
263	Development of Drug-Induced Cutaneous Vasculitis in a Patient with Relapsed Angioimmunoblastic T-cell Lymphoma Treated with Novel Bortezomib and Panobinostat Combination: A Possible Surrogate Marker of Response. Cancer Science & Research Open Access, 2014, 1, 1-4.	1.4	0
264	Targeted Cancer Therapy. Nishinon Journal of Dermatology, 2016, 78, 221-228.	0.0	0
266	Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas. Advances in Experimental Medicine and Biology, 2021, 1283, 73-84.	0.8	3
267	Review of the treatment of mycosis fungoides and SÅ©zary syndrome: A stage-based approach. International Journal of Health Sciences, 2013, 7, 220-39.	0.4	10
268	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Current Pharmaceutical Design, 2013, 19, 734-44.	0.9	23
269	Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. EXCLI Journal, 2014, 13, 954-76.	0.5	6
270	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Bioorganic and Medicinal Chemistry, 2022, 56, 116599.	1.4	5
271	The tubulin code in platelet biogenesis.. Seminars in Cell and Developmental Biology, 2022, , .	2.3	2
272	Panobinostat, a Pan-HDAC Inhibitor, Substantially Decreases the Quiescent Population of Leukemic Cells either in Monoculture or in Co-culture with Bone Marrow Stromal Cells.. International Journal of Cancer Management, 2022, 15, .	0.2	1
274	Singleâ€cell profilingâ€guided combination therapy of câ€Fos and histone deacetylase inhibitors in diffuse large Bâ€cell lymphoma. Clinical and Translational Medicine, 2022, 12, e798.	1.7	10
275	Discovery of Histone Deacetylase Inhibitor Using Molecular Modeling and Free Energy Calculations. ACS Omega, 2022, 7, 18786-18794.	1.6	5
276	Clinical Applications of Histone Deacetylase Inhibitors. , 2023, , 793-819.		0
277	Evaluation of Small-Molecule HDAC Inhibitors Through In Vitro and In Cellulo Approaches. Methods in Molecular Biology, 2023, , 157-177.	0.4	0
278	Cutaneous Tâ€cell lymphomas: 2023 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2023, 98, 193-209.	2.0	12
279	DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro. Frontiers in Genetics, 0, 13, .	1.1	0



#	ARTICLE	IF	CITATIONS
280	Recent advances in epigenetic anticancer therapeutics and future perspectives. <i>Frontiers in Genetics</i> , 2023, 14, 1187277. doi:10.3389/fgen.2023.1187277	1.1	3
281	Clinical advances in epigenetic therapies for lymphoma. <i>Clinical Epigenetics</i> , 2023, 15, 1000000. doi:10.1186/s13040-023-00000-0	1.8	3